Literature DB >> 11171913

Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET.

H Shinotoh1, A Aotsuka, K Fukushi, S Nagatsuka, N Tanaka, T Ota, S Tanada, T Irie.   

Abstract

Acetylcholinesterase (AChE) activities in the brain of three patients with AD were measured once before and once during donepezil treatment (5 mg/d in two patients, 3 mg/d in one patient) using PET and N-[11C]methylpiperidin-4-yl acetate. Donepezil reduced k(3) values, an index of AChE activity, in the cerebral cortex by 39 +/- 5%. All patients showed some degree of symptomatic improvement, and it was concluded that this improvement was likely caused by improved cholinergic activity by inhibition of AChE in the brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11171913     DOI: 10.1212/wnl.56.3.408

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  19 in total

1.  Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.

Authors:  N I Bohnen; D I Kaufer; R Hendrickson; L S Ivanco; B J Lopresti; R A Koeppe; C C Meltzer; G Constantine; J G Davis; C A Mathis; S T Dekosky; R Y Moore
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

2.  Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with (11)C-SA4503 and microPET.

Authors:  Nisha K Ramakrishnan; Anniek K D Visser; Marianne Schepers; Gert Luurtsema; Csaba J Nyakas; Philip H Elsinga; Kiichi Ishiwata; Rudi A J O Dierckx; Aren van Waarde
Journal:  Psychopharmacology (Berl)       Date:  2014-03-18       Impact factor: 4.530

3.  Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease.

Authors:  Martijn L T M Müller; Roger L Albin; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Kirk A Frey; Nicolaas I Bohnen
Journal:  Brain       Date:  2013-09-20       Impact factor: 13.501

4.  Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS.

Authors:  S G Mueller; N Schuff; M W Weiner
Journal:  NMR Biomed       Date:  2006-10       Impact factor: 4.044

5.  Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.

Authors:  Stefan J Teipel; Alexander Drzezga; Peter Bartenstein; Hans-Jürgen Möller; Markus Schwaiger; Harald Hampel
Journal:  Psychopharmacology (Berl)       Date:  2006-06-01       Impact factor: 4.530

Review 6.  The application of positron-emitting molecular imaging tracers in Alzheimer's disease.

Authors:  Robert M Cohen
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

7.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

8.  Syndromic approach to Parkinson's disease: role of functional imaging.

Authors:  Chong Sik Lee; Sun Ju Chung; Jae Seung Kim
Journal:  J Clin Neurol       Date:  2006-06-20       Impact factor: 3.077

Review 9.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease.

Authors:  Nobuyuki Okamura; Yoshihito Funaki; Manabu Tashiro; Motohisa Kato; Yoichi Ishikawa; Masahiro Maruyama; Hiroyasu Ishikawa; Kenichi Meguro; Ren Iwata; Kazuhiko Yanai
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.